查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1855044

幹細胞製造的全球市場:各產品，各用途，各流通管道，各終端用戶，各地區-市場規模，產業動態，機會分析，預測(2025年～2033年)

Global Stem Cell Manufacturing Market: By Product, Application, Distribution Channel, End Users, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 421 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

在臨床研究取得重大成功以及新療法獲準的推動下，幹細胞製造領域正經歷快速發展，這些成功和新療法正在改變再生醫學領域。這些進展驗證了幹細胞技術的治療潛力，激發了研究人員、投資者和醫療保健提供者的興趣和信心。因此，該市場經歷了顯著成長，預計到 2024 年市場規模將達到約 242.6 億美元。這一成長趨勢預計將持續，市場估計和預測顯示，到 2033 年，該市場規模將達到 654.9 億美元。在預測期（2025-2033 年）內，該市場複合年增長率 (CAGR) 為 11.96%，展現出強勁的發展勢頭和不斷擴大的行業成長機會。

這項快速擴張主要得益於策略性外包的激增以及大型製藥公司投資的增加。這些合作和資金投入對於解決長期存在的生產瓶頸至關重要，這些瓶頸一直限制著幹細胞療法的規模化和成本效益。透過與專業的合約生產組織 (CMO) 合作並投資於尖端生產技術，製藥公司正在增強其生產能力並簡化流程。這種策略性外包方法不僅緩解了營運限制，還加快了療法的商業化和全球市場上市速度。

值得關注的市場動態

幹細胞生產市場的關鍵參與者正在進行大量投資以滿足預期需求。產業領導者 Lonza 已在其位於 Vacaville 的工廠投資約 5 億瑞士法郎，該工廠目前已擁有約 33 萬公升的生物反應器產能。這項重大投資體現了龍沙公司致力於擴展其製造基礎設施，以滿足再生醫學和細胞療法開發商日益增長的需求的戰略重點。

同樣，賽默飛世爾科技公司也採取大膽舉措，加強其研發和製造能力。該公司正在研發領域投資14億美元，光在紐約市就將其製造規模擴大了45,000多平方英尺。此次擴張是其更廣泛策略的一部分，旨在提高生產效率、加速創新並支持其幹細胞療法產品線的擴展。賽默飛世爾對研發和基礎設施的雙重投入，凸顯了將科學進步與可擴展製造解決方案結合的重要性。

此外，龍沙公司正在休士頓開發一座30萬平方英尺的新工廠，進一步凸顯了該產業積極擴大產能的策略。此次擴建不僅體現了龍沙致力於滿足未來商業需求的決心，也反映了乾細胞生產市場建設能夠實現大規模生產的先進設施的更廣泛趨勢。

核心驅動因素

慢性病的日益增多是推動再生醫學市場（包括幹細胞生產）成長的關鍵因素。糖尿病、心血管疾病、神經退化性疾病和自體免疫疾病等慢性病在全球日益普遍，給醫療保健系統和患者帶來了沉重的負擔。傳統療法通常側重於症狀管理而非治愈，因此，人們迫切需要能夠修復或替換受損組織並恢復正常功能的創新療法。再生醫學可望利用人體自身的癒合機制，為解決這些尚未滿足的醫療需求提供了一條充滿希望​​的途徑。

新商機趨勢

將人工智慧 (AI) 整合到預測性品質控制 (QC) 中，預計將為幹細胞生產市場帶來變革性機遇，顯著提高效率和產品可靠性。傳統的幹細胞生產品質控制方法通常依賴人工檢查和定期抽樣，這些方法耗時且容易出現誤差。相較之下，基於人工智慧的系統利用先進的演算法，能夠即時處理大量數據，從而實現對生產過程的持續監控和潛在問題的早期檢測。這種能力不僅提高了品質評估的準確性，還降低了批次缺陷的風險，並提高了整體生產產量和一致性。

優化障礙

幹細胞療法的高昂生產成本和固有的生產複雜性構成了重大挑戰，可能會阻礙這些療法的廣泛應用並減緩市場成長。幹細胞生產涉及複雜的流程，需要嚴格遵守品質標準、無菌環境和專用設備。這些因素推高了生產成本，可能導致許多醫療機構和患者難以負擔治療費用。這些成本驅動的經濟障礙限制了治療的可近性和普及，尤其是在預算有限的地區和醫療系統中。

目錄

第1章 調查架構

  • 調查目的
  • 產品概要
  • 市場區隔

第2章 調查手法

  • 定性調查
    • 一級資訊來源·二級資訊來源
  • 定量調查
    • 一級資訊來源·二級資訊來源
  • 初步調查受訪者的明細:各地區
  • 調查的前提條件
  • 市場規模·估計
  • 資料的三角測量

第3章 摘要整理:幹細胞製造的全球市場

第4章 幹細胞製造的全球市場概要

  • 產業價值鏈分析
    • 材料供應商
    • 製造商
    • 銷售商
    • 終端用戶
  • 產業展望
    • 全球GDP與醫療保健基礎設施
    • 製藥、生物技術和CRO/CDMO的成長
    • 慢性病負擔加重
    • 從幹細胞實驗室研究到核准臨床療法的轉變
    • 幹細胞生產流程與新興技術
    • 常用幹細胞型
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商業者的威脅
    • 競爭的程度
  • 市場動態和趨勢
    • 促進因素
    • 課題
    • 機會
    • 主要趨勢
  • 市場成長與展望
    • 市場收益估計·預測，2020年～2033年
    • 價格趨勢分析
  • 競爭儀表板
    • 市場集中率
    • 企業佔有率分析(金額%)、2024年
    • 競爭的製圖和基準

第5章 幹細胞製造的全球市場分析:各產品類型

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 幹細胞線
    • 消耗品和套件
    • 設備
    • 軟體和服務

第6章 幹細胞製造的全球市場分析:各用途

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 研究用途
    • 臨床用途
    • 細胞·組織銀行

第7章 幹細胞製造的全球市場分析:各流通管道

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 直銷
    • 經銷商

第8章 幹細胞製造的全球市場分析:各終端用戶

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • CRO，製藥，生物科技企業
    • 學術·研究機關
    • 醫院·手術中心
    • 細胞·組織銀行
    • 其他的用戶(再生醫療Start-Ups，診斷公司)

第9章 幹細胞製造的全球市場分析:各地區

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第10章 北美的幹細胞製造市場分析

第11章 歐洲的幹細胞製造市場分析

第12章 亞太地區的幹細胞製造市場分析

第13章 中東·非洲的幹細胞製造市場分析

第14章 南美的幹細胞製造市場分析

第15章 企業簡介

  • Thermo Fisher Scientific
  • Lonza
  • nacalai
  • BioRad
  • Merck
  • FujiFilm
  • CellGenix
  • Teknova
  • Sartorius
  • Stemcell Technologies
  • Miltenyi Biotec
  • Eppendorf
  • Beckman Coulter
  • Takara Bio
  • Bio-Techne
  • PromoCell
  • Wellsky
  • BD
  • Corning Life Sciences
  • HiMedia
  • REPROCELL
  • Other Prominent Players

第16章 附錄

簡介目錄
Product Code: AA09251517

The stem cell manufacturing landscape is evolving rapidly, fueled by significant clinical trial successes and the approval of new therapies that are transforming the regenerative medicine field. These advancements have validated the therapeutic potential of stem cell technologies, driving increased interest and confidence among researchers, investors, and healthcare providers. As a result, the market has experienced substantial growth, with its valuation reaching approximately US$ 24.26 billion in 2024. This upward trajectory is expected to continue, with projections estimating the market will expand to a remarkable US$ 65.49 billion by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 11.96% during the forecast period from 2025 to 2033, underscoring the strong momentum and expanding opportunities within the industry.

A key factor contributing to this rapid expansion is the surge in strategic outsourcing and increased investments from major pharmaceutical companies. These collaborations and financial commitments are crucial in addressing longstanding manufacturing bottlenecks that have challenged the scalability and cost-effectiveness of stem cell therapies. By partnering with specialized contract manufacturing organizations (CMOs) and investing in cutting-edge production technologies, pharmaceutical players are enhancing manufacturing capacity and streamlining processes. This strategic outsourcing not only alleviates operational constraints but also accelerates the pace at which therapies can be commercialized and brought to market on a global scale.

Noteworthy Market Developments

Leading corporations in the stem cell manufacturing market are making substantial investments to position themselves for anticipated future demand, signaling a robust commitment to scaling production capabilities and advancing the field. Lonza, a key player in the industry, is investing approximately 500 million Swiss francs into its Vacaville facility, which already features an impressive bioreactor capacity of around 330,000 liters. This significant financial commitment reflects Lonza's strategic focus on expanding its manufacturing infrastructure to meet the growing needs of regenerative medicine and cell therapy developers.

Similarly, Thermo Fisher Scientific is making bold moves to enhance its research and manufacturing capabilities. The company is investing $1.4 billion in research and development, alongside expanding its manufacturing footprint by more than 45,000 square feet in New York alone. This expansion is part of a broader strategy to increase production efficiency, accelerate innovation, and support a growing pipeline of stem cell therapies. Thermo Fisher's commitment to both R&D and physical infrastructure highlights the critical importance of integrating scientific advancement with scalable manufacturing solutions.

Adding to this momentum, Lonza is also developing a new 300,000-square-foot facility in Houston, further emphasizing the industry's aggressive approach to scaling capacity. This expansion not only demonstrates Lonza's dedication to meeting future commercial demand but also reflects a broader trend within the stem cell manufacturing market toward building state-of-the-art facilities capable of supporting high-volume production.

Core Growth Drivers

The rising prevalence of chronic diseases is a significant factor driving the growth of the regenerative medicine market, including stem cell manufacturing. Chronic illnesses such as diabetes, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions have become increasingly common worldwide, placing a substantial burden on healthcare systems and patients alike. Traditional treatment options often focus on managing symptoms rather than offering curative solutions, leading to a growing demand for innovative therapies that can repair or replace damaged tissues and restore normal function. Regenerative medicine, with its potential to harness the body's own healing mechanisms, presents a promising avenue for addressing these unmet medical needs.

Emerging Opportunity Trends

The integration of artificial intelligence (AI) into predictive quality control (QC) represents a transformative opportunity for the stem cell manufacturing market, promising to significantly enhance efficiency and product reliability. Traditional QC methods in stem cell manufacturing often rely on manual inspections and periodic sampling, which can be time-consuming and prone to inconsistencies. In contrast, AI-driven systems leverage advanced algorithms capable of processing vast amounts of data in real time, allowing for continuous monitoring and early detection of potential issues during the manufacturing process. This capability not only improves the accuracy of quality assessments but also reduces the risk of batch failures, thereby increasing overall manufacturing yield and consistency.

Barriers to Optimization

High manufacturing costs and the inherent complexity of producing stem cell therapies pose significant challenges that could impede the widespread adoption of these treatments and potentially slow market growth. Stem cell manufacturing involves intricate processes that demand strict adherence to quality standards, sterile environments, and specialized equipment. These factors contribute to elevated production expenses, which in turn can make therapies prohibitively expensive for many healthcare providers and patients. The financial barrier created by these costs limits accessibility and adoption, especially in regions or healthcare systems with constrained budgets.

Detailed Market Segmentation

By Product Type, the consumables and kits segment holds a crucial position within the stem cell manufacturing market, commanding a substantial revenue share of 42.51%. This segment forms the backbone of the entire industry, as consumables and kits are indispensable at every stage of the stem cell lifecycle-from initial research and development to scale-up and commercial production. The recurring nature of demand for these products stems from their essential role in maintaining cell viability, supporting cell growth, and ensuring the precision required for consistent manufacturing outcomes. Without reliable and high-quality consumables, the entire process of stem cell manufacturing would face significant challenges, making this segment foundational to the industry's overall success.

By Distribution Channel, the direct sales channel dominates the stem cell manufacturing market, generating over 69.93% of the total market revenue. This overwhelming share is largely attributed to the highly sensitive and complex nature of stem cell products, which demand specialized handling and distribution processes. Unlike conventional pharmaceutical products, stem cell therapies are living biological materials that require precise conditions to maintain their viability and therapeutic efficacy. The intricate nature of these products necessitates direct interaction between manufacturers and end-users, such as hospitals, clinics, and research institutions, ensuring strict quality control and compliance with regulatory standards throughout the supply chain.

By End Users, Pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are controlling the largest 44.67% market share. There are a few companies that hold the dominant position in the market, but they are collectively the commercial engine of the industry. These entities in the stem cell manufacturing market possess the financial resources, infrastructure, and regulatory expertise necessary to navigate the long and expensive path from research to commercialization.

By Application, the clinical applications segment holds a commanding position within the stem cell manufacturing market, accounting for 52.32% of the total market share. This significant share reflects the critical role clinical applications play in transforming the scientific potential of stem cell research into real-world medical treatments. As the field of regenerative medicine continues to advance, clinical applications serve as the primary avenue through which promising laboratory discoveries are translated into therapies that can improve patient outcomes. The emphasis on clinical use underscores the growing confidence in stem cell technologies as viable treatment options for a range of diseases and conditions.

Segment Breakdown

By Product

  • Stem Cell Lines
  • Mesenchymal Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Induced Pluripotent Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Hematopoietic Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Embryonic Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Neural Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Others
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Consumables and Kits

By Type

  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • T-Flasks
  • Vials
  • Cell Culture Dishes / Multi-Well Plates
  • Cell Culture Bags
  • Others
  • Others

By Application

  • Research Applications
  • Disease Modelling
  • Drug Discovery & Toxicology Testing
  • Others
  • Clinical Applications
  • Autologous Therapies
  • Allogeneic Therapies
  • Cell & Tissue Banking
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Software and Services

By Application

  • Research Applications
  • Disease Modelling
  • Drug Discovery & Toxicology Testing
  • Others
  • Clinical Applications
  • Autologous Therapies
  • Allogeneic Therapies
  • Cell & Tissue Banking

By Distribution Channel

  • Direct Sales
  • Distributors

By End User

  • CROs, Pharmaceutical and Biotechnology Companies
  • Academic & Research Institutions
  • Hospitals & Surgical Centres
  • Cell & Tissue Banks
  • Other Users (Regenerative Medicine Startups, Diagnostic Firms)

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Cambodia
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America stands out as the undisputed global leader in the stem cell manufacturing market, propelled by a strong blend of well-established regulatory frameworks, significant public funding, and a thriving biotechnology ecosystem. The region's dominance is anchored by its ability to create a conducive environment for research, development, and commercialization of stem cell technologies. Regulatory agencies in the United States and Canada have developed clear and structured pathways that facilitate the approval and oversight of stem cell products, giving companies the confidence to invest heavily in innovation and scale-up manufacturing capabilities. This regulatory clarity is a critical factor that distinguishes North America from other regions, reducing uncertainties and accelerating the time to market for new therapies.
  • The market's anticipated share of over 49.58% by 2033 highlights North America's commanding presence in the industry. This leading position is reinforced by the substantial financial resources directed toward stem cell research and manufacturing infrastructure. Both federal and state governments in the U.S. have launched initiatives and funding programs that support biotechnology ventures, clinical trials, and manufacturing advancements. These investments not only stimulate industry growth but also foster collaboration between academia, private companies, and healthcare providers.

Leading Market Participants

  • Thermo Fisher Scientific
  • Lonza
  • nacalai
  • BioRad
  • Merck
  • FujiFilm
  • CellGenix
  • Teknova
  • Sartorius
  • Stemcell Technologies
  • Miltenyi Biotec
  • Eppendorf
  • Beckman Coulter
  • Takara Bio
  • Bio-Techne
  • PromoCell
  • Wellsky
  • BD
  • Corning Life Sciences
  • HiMedia
  • REPROCELL
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Stem Cell Manufacturing Market

Chapter 4. Global Stem Cell Manufacturing Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Global GDP and Healthcare Infrastructure
    • 4.2.2. Growth in Pharmaceutical, Biotechnology, and CRO/CDMO
    • 4.2.3. Growing Chronic Disease Burden
    • 4.2.4. Transition from Stem Cell Experimental Research to Approved Clinical Therapies
    • 4.2.5. Stem Cell Manufacturing Workflow and Emerging Technologies
      • 4.2.5.1. Embryonic Stem Cells (ESCs)
      • 4.2.5.2. Induced Pluripotent Stem Cells (iPSCs)
      • 4.2.5.3. Adult Stem Cells (ASCs)
    • 4.2.6. Commonly Used Stem Cell Types
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Degree of Competition
  • 4.4. Market Dynamics and Trends
    • 4.4.1. Growth Drivers
    • 4.4.2. Challenges
    • 4.4.3. Opportunity
    • 4.4.4. Key Trends
  • 4.5. Market Growth and Outlook
    • 4.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
    • 4.5.2. Price Trend Analysis
  • 4.6. Competition Dashboard
    • 4.6.1. Market Concentration Rate
    • 4.6.2. Company Market Share Analysis (Value %), 2024
    • 4.6.3. Competitor Mapping & Benchmarking

Chapter 5. Global Stem Cell Manufacturing Market Analysis, By Product Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 5.2.1. Stem Cell Lines
      • 5.2.1.1. Mesenchymal Stem Cells
        • 5.2.1.1.1. Differentiated
          • 5.2.1.1.1.1. Instruments
  • 5.2.1.1.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.1.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.1.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.1.1.2. Consumables and Kits
  • 5.2.1.1.1.2.1. Culture Media
  • 5.2.1.1.1.2.2. Growth Factors & Cytokines
  • 5.2.1.1.1.2.3. Culture ware and Vessels
        • 5.2.1.1.2. Undifferentiated
          • 5.2.1.1.2.1. Instruments
  • 5.2.1.1.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.1.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.1.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.1.2.2. Consumables and Kits
  • 5.2.1.1.2.2.1. Culture Media
  • 5.2.1.1.2.2.2. Growth Factors & Cytokines
  • 5.2.1.1.2.2.3. Culture ware and Vessels
      • 5.2.1.2. Induced Pluripotent Stem Cells
        • 5.2.1.2.1. Differentiated
          • 5.2.1.2.1.1. Instruments
  • 5.2.1.2.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.2.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.2.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.2.1.2. Consumables and Kits
  • 5.2.1.2.1.2.1. Culture Media
  • 5.2.1.2.1.2.2. Growth Factors & Cytokines
  • 5.2.1.2.1.2.3. Culture ware and Vessels
        • 5.2.1.2.2. Undifferentiated
          • 5.2.1.2.2.1. Instruments
  • 5.2.1.2.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.2.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.2.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.2.2.2. Consumables and Kits
  • 5.2.1.2.2.2.1. Culture Media
  • 5.2.1.2.2.2.2. Growth Factors & Cytokines
  • 5.2.1.2.2.2.3. Culture ware and Vessels
      • 5.2.1.3. Hematopoietic Stem Cells
        • 5.2.1.3.1. Differentiated
          • 5.2.1.3.1.1. Instruments
  • 5.2.1.3.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.3.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.3.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.3.1.2. Consumables and Kits
  • 5.2.1.3.1.2.1. Culture Media
  • 5.2.1.3.1.2.2. Growth Factors & Cytokines
  • 5.2.1.3.1.2.3. Culture ware and Vessels
        • 5.2.1.3.2. Undifferentiated
          • 5.2.1.3.2.1. Instruments
  • 5.2.1.3.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.3.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.3.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.3.2.2. Consumables and Kits
  • 5.2.1.3.2.2.1. Culture Media
  • 5.2.1.3.2.2.2. Growth Factors & Cytokines
  • 5.2.1.3.2.2.3. Culture ware and Vessels
      • 5.2.1.4. Embryonic Stem Cells
        • 5.2.1.4.1. Differentiated
          • 5.2.1.4.1.1. Instruments
  • 5.2.1.4.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.4.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.4.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.4.1.2. Consumables and Kits
  • 5.2.1.4.1.2.1. Culture Media
  • 5.2.1.4.1.2.2. Growth Factors & Cytokines
  • 5.2.1.4.1.2.3. Culture ware and Vessels
        • 5.2.1.4.2. Undifferentiated
          • 5.2.1.4.2.1. Instruments
  • 5.2.1.4.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.4.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.4.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.4.2.2. Consumables and Kits
  • 5.2.1.4.2.2.1. Culture Media
  • 5.2.1.4.2.2.2. Growth Factors & Cytokines
  • 5.2.1.4.2.2.3. Culture ware and Vessels
      • 5.2.1.5. Neural Stem Cells
        • 5.2.1.5.1. Differentiated
          • 5.2.1.5.1.1. Instruments
  • 5.2.1.5.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.5.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.5.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.5.1.2. Consumables and Kits
  • 5.2.1.5.1.2.1. Culture Media
  • 5.2.1.5.1.2.2. Growth Factors & Cytokines
  • 5.2.1.5.1.2.3. Culture ware and Vessels
        • 5.2.1.5.2. Undifferentiated
          • 5.2.1.5.2.1. Instruments
  • 5.2.1.5.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.5.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.5.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.5.2.2. Consumables and Kits
  • 5.2.1.5.2.2.1. Culture Media
  • 5.2.1.5.2.2.2. Growth Factors & Cytokines
  • 5.2.1.5.2.2.3. Culture ware and Vessels
      • 5.2.1.6. Others
        • 5.2.1.6.1. Differentiated
          • 5.2.1.6.1.1. Instruments
  • 5.2.1.6.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.6.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.6.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.6.1.2. Consumables and Kits
  • 5.2.1.6.1.2.1. Culture Media
  • 5.2.1.6.1.2.2. Growth Factors & Cytokines
  • 5.2.1.6.1.2.3. Culture ware and Vessels
        • 5.2.1.6.2. Undifferentiated
          • 5.2.1.6.2.1. Instruments
  • 5.2.1.6.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.6.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.6.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.6.2.2. Consumables and Kits
  • 5.2.1.6.2.2.1. Culture Media
  • 5.2.1.6.2.2.2. Growth Factors & Cytokines
  • 5.2.1.6.2.2.3. Culture ware and Vessels
    • 5.2.2. Consumables and Kits
      • 5.2.2.1. By Type
        • 5.2.2.1.1. Culture Media
        • 5.2.2.1.2. Growth Factors & Cytokines
        • 5.2.2.1.3. Culture ware and Vessels
          • 5.2.2.1.3.1. T-Flasks
          • 5.2.2.1.3.2. Vials
          • 5.2.2.1.3.3. Cell Culture Dishes / Multi-Well Plates
          • 5.2.2.1.3.4. Cell Culture Bags
          • 5.2.2.1.3.5. Others
        • 5.2.2.1.4. Others
      • 5.2.2.2. By Application
        • 5.2.2.2.1. Research Applications
          • 5.2.2.2.1.1. Disease Modelling
          • 5.2.2.2.1.2. Drug Discovery & Toxicology Testing
          • 5.2.2.2.1.3. Others
        • 5.2.2.2.2. Clinical Applications
          • 5.2.2.2.2.1. Autologous Therapies
          • 5.2.2.2.2.2. Allogeneic Therapies
        • 5.2.2.2.3. Cell & Tissue Banking
    • 5.2.3. Instruments
      • 5.2.3.1. Bioreactors & Cell Expansion Systems
      • 5.2.3.2. Cell Sorters & Separation Devices
      • 5.2.3.3. Flow Cytometers & Analysers
    • 5.2.4. Software and Services

Chapter 6. Global Stem Cell Manufacturing Market Analysis, By Application

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 6.2.1. Research Applications
      • 6.2.1.1. Disease Modelling
      • 6.2.1.2. Drug Discovery & Toxicology Testing
      • 6.2.1.3. Others
    • 6.2.2. Clinical Applications
      • 6.2.2.1. Autologous Therapies
      • 6.2.2.2. Allogeneic Therapies
    • 6.2.3. Cell & Tissue Banking

Chapter 7. Global Stem Cell Manufacturing Market Analysis, By Distribution Channel

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 7.2.1. Direct Sales
    • 7.2.2. Distributors

Chapter 8. Global Stem Cell Manufacturing Market Analysis, By End Users

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 8.2.1. CROs, Pharmaceutical and Biotechnology Companies
    • 8.2.2. Academic & Research Institutions
    • 8.2.3. Hospitals & Surgical Centres
    • 8.2.4. Cell & Tissue Banks
    • 8.2.5. Other Users (Regenerative Medicine Startups, Diagnostic Firms)

Chapter 9. Global Stem Cell Manufacturing Market Analysis, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
      • 9.2.2.1. Western Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Rest of Western Europe
      • 9.2.2.2. Eastern Europe
        • 9.2.2.2.1. Poland
        • 9.2.2.2.2. Russia
        • 9.2.2.2.3. Rest of Eastern Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. South Korea
      • 9.2.3.5. Australia & New Zealand
      • 9.2.3.6. ASEAN
        • 9.2.3.6.1. Cambodia
        • 9.2.3.6.2. Indonesia
        • 9.2.3.6.3. Malaysia
        • 9.2.3.6.4. Philippines
        • 9.2.3.6.5. Singapore
        • 9.2.3.6.6. Thailand
        • 9.2.3.6.7. Vietnam
      • 9.2.3.7. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Rest of South America

Chapter 10. North America Stem Cell Manufacturing Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By End Users
    • 10.2.5. By Country

Chapter 11. Europe Stem Cell Manufacturing Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 11.2.1. By Product Type
    • 11.2.2. By Application
    • 11.2.3. By Distribution Channel
    • 11.2.4. By End Users
    • 11.2.5. By Country

Chapter 12. Asia Pacific Stem Cell Manufacturing Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 12.2.1. By Product Type
    • 12.2.2. By Application
    • 12.2.3. By Distribution Channel
    • 12.2.4. By End Users
    • 12.2.5. By Country

Chapter 13. Middle East & Africa Stem Cell Manufacturing Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 13.2.1. By Product Type
    • 13.2.2. By Application
    • 13.2.3. By Distribution Channel
    • 13.2.4. By End Users
    • 13.2.5. By Country

Chapter 14. South America Stem Cell Manufacturing Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 14.2.1. By Product Type
    • 14.2.2. By Application
    • 14.2.3. By Distribution Channel
    • 14.2.4. By End Users
    • 14.2.5. By Country

Chapter 15. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 15.1. Thermo Fisher Scientific
  • 15.2. Lonza
  • 15.3. nacalai
  • 15.4. BioRad
  • 15.5. Merck
  • 15.6. FujiFilm
  • 15.7. CellGenix
  • 15.8. Teknova
  • 15.9. Sartorius
  • 15.10. Stemcell Technologies
  • 15.11. Miltenyi Biotec
  • 15.12. Eppendorf
  • 15.13. Beckman Coulter
  • 15.14. Takara Bio
  • 15.15. Bio-Techne
  • 15.16. PromoCell
  • 15.17. Wellsky
  • 15.18. BD
  • 15.19. Corning Life Sciences
  • 15.20. HiMedia
  • 15.21. REPROCELL
  • 15.22. Other Prominent Players

Chapter 16. Annexure

  • 16.1. List of Secondary Sources
  • 16.2. Key Country Markets - Macro Economic Outlook/Indicator